Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.019x
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a cash flow conversion efficiency ratio of 0.019x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥43.77 Million) by net assets (CN¥2.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
0.052x |
|
DIGITAL CORE REIT
PINK:DGTCF
|
N/A |
|
KSB Ltd
NSE:KSB
|
0.001x |
|
Nagacorp Ltd
PINK:NGCRF
|
0.072x |
|
Jinxiandai Information Industry Co
SHE:300830
|
0.012x |
|
SK Chemicals Co Ltd
KO:285130
|
0.016x |
|
TOYO ENGINEERG-6330-
F:6AE
|
N/A |
|
Varex Imaging Corp
NASDAQ:VREX
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.31 Billion | CN¥-14.77 Million | -0.006x | -121.28% |
| 2023-12-31 | CN¥2.36 Billion | CN¥71.02 Million | 0.030x | -58.95% |
| 2022-12-31 | CN¥2.25 Billion | CN¥165.27 Million | 0.073x | -40.27% |
| 2021-12-31 | CN¥2.19 Billion | CN¥268.90 Million | 0.123x | +118.28% |
| 2020-12-31 | CN¥2.01 Billion | CN¥113.00 Million | 0.056x | -80.50% |
| 2019-12-31 | CN¥933.15 Million | CN¥269.23 Million | 0.289x | +64.76% |
| 2018-12-31 | CN¥993.28 Million | CN¥173.94 Million | 0.175x | +265.92% |
| 2017-12-31 | CN¥892.48 Million | CN¥42.71 Million | 0.048x | -70.28% |
| 2016-12-31 | CN¥873.05 Million | CN¥140.57 Million | 0.161x | +28.05% |
| 2015-12-31 | CN¥765.84 Million | CN¥96.30 Million | 0.126x | -3.74% |
| 2014-12-31 | CN¥676.42 Million | CN¥88.36 Million | 0.131x | -17.35% |
| 2013-12-31 | CN¥565.92 Million | CN¥89.44 Million | 0.158x | -62.69% |
| 2012-12-31 | CN¥260.11 Million | CN¥110.19 Million | 0.424x | +71.76% |
| 2011-12-31 | CN¥201.07 Million | CN¥49.59 Million | 0.247x | +685.36% |
| 2010-12-31 | CN¥168.71 Million | CN¥-7.11 Million | -0.042x | -191.84% |
| 2009-12-31 | CN¥168.37 Million | CN¥7.72 Million | 0.046x | +121.91% |
| 2008-12-31 | CN¥75.88 Million | CN¥-15.89 Million | -0.209x | +13.44% |
| 2007-12-31 | CN¥71.04 Million | CN¥-17.18 Million | -0.242x | -14.96% |
| 2006-12-31 | CN¥101.70 Million | CN¥-21.40 Million | -0.210x | -- |